Repurposing With Purpose: Treatment of Bachmann–Bupp Syndrome With Eflornithine and Implications for Other Polyaminopathies

The article explores the use of eflornithine (DFMO) to treat Bachmann–Bupp Syndrome (BABS), a rare neurodevelopmental disorder characterized by developmental delay, alopecia, and other symptoms due to ODC1 gene mutations. In a study involving 6 patients, DFMO showed improvements in muscle tone, developmental milestones, and hair regrowth. The research underscores the potential of drug repurposing for rare diseases, despite challenges like intellectual property issues and small patient populations. It also highlights the role of AI and machine learning in enhancing therapeutic predictions and the importance of international collaborations and patient advocacy in advancing treatments for rare conditions.